Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aspergillus niger | 3 | 2021 | 21 | 1.290 |
Why?
|
| STAT6 Transcription Factor | 3 | 2022 | 38 | 1.260 |
Why?
|
| Asthma | 5 | 2022 | 810 | 1.190 |
Why?
|
| Pulmonary Aspergillosis | 2 | 2021 | 11 | 1.170 |
Why?
|
| Sinusitis | 2 | 2022 | 119 | 0.860 |
Why?
|
| Spores, Fungal | 1 | 2021 | 15 | 0.750 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2021 | 8 | 0.750 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2021 | 38 | 0.740 |
Why?
|
| Lung | 5 | 2022 | 1553 | 0.720 |
Why?
|
| Eosinophilia | 1 | 2022 | 106 | 0.690 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 2 | 2021 | 20 | 0.680 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 321 | 0.650 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 91 | 0.570 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 138 | 0.530 |
Why?
|
| Hypersensitivity | 2 | 2021 | 198 | 0.500 |
Why?
|
| Peptidomimetics | 1 | 2015 | 14 | 0.490 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 407 | 0.480 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 65 | 0.470 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 124 | 0.440 |
Why?
|
| Th2 Cells | 2 | 2021 | 191 | 0.430 |
Why?
|
| CD11a Antigen | 1 | 2013 | 14 | 0.420 |
Why?
|
| Leishmania major | 1 | 2013 | 29 | 0.420 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2013 | 49 | 0.410 |
Why?
|
| Bronchoconstriction | 2 | 2021 | 18 | 0.310 |
Why?
|
| Mice | 7 | 2022 | 18808 | 0.240 |
Why?
|
| Eosinophils | 2 | 2021 | 128 | 0.210 |
Why?
|
| Soot | 1 | 2022 | 15 | 0.200 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 319 | 0.200 |
Why?
|
| Aspergillus | 1 | 2022 | 27 | 0.190 |
Why?
|
| Animals | 8 | 2022 | 36266 | 0.190 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 41 | 0.190 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 83 | 0.180 |
Why?
|
| Candida albicans | 1 | 2021 | 90 | 0.180 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2020 | 14 | 0.170 |
Why?
|
| Host-Parasite Interactions | 1 | 2020 | 83 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 215 | 0.170 |
Why?
|
| Candidiasis | 1 | 2021 | 138 | 0.170 |
Why?
|
| Helminths | 1 | 2020 | 48 | 0.170 |
Why?
|
| Mycoses | 1 | 2021 | 121 | 0.170 |
Why?
|
| Helminthiasis | 1 | 2020 | 80 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 266 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4742 | 0.150 |
Why?
|
| Blood Platelets | 1 | 2021 | 341 | 0.150 |
Why?
|
| src Homology Domains | 1 | 2018 | 36 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 4786 | 0.150 |
Why?
|
| Lung Diseases, Fungal | 1 | 2018 | 33 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 159 | 0.140 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 612 | 0.130 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 154 | 0.130 |
Why?
|
| Salmeterol Xinafoate | 1 | 2015 | 14 | 0.130 |
Why?
|
| beta-Arrestins | 1 | 2015 | 34 | 0.120 |
Why?
|
| Arrestins | 1 | 2015 | 30 | 0.120 |
Why?
|
| Formoterol Fumarate | 1 | 2015 | 34 | 0.120 |
Why?
|
| Propanolamines | 1 | 2015 | 33 | 0.120 |
Why?
|
| Carbazoles | 1 | 2015 | 35 | 0.120 |
Why?
|
| Albuterol | 1 | 2015 | 53 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 2018 | 309 | 0.120 |
Why?
|
| Inflammation | 2 | 2022 | 1598 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 90 | 0.120 |
Why?
|
| Th1-Th2 Balance | 1 | 2013 | 9 | 0.110 |
Why?
|
| Cell Line | 1 | 2018 | 2833 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2013 | 363 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 1793 | 0.090 |
Why?
|
| Gene Expression | 1 | 2015 | 1612 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 1079 | 0.090 |
Why?
|
| Interleukin-13 | 1 | 2010 | 101 | 0.080 |
Why?
|
| Immunity | 2 | 2021 | 188 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 895 | 0.080 |
Why?
|
| Cell Movement | 1 | 2013 | 916 | 0.080 |
Why?
|
| Respiratory System | 2 | 2021 | 100 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3956 | 0.070 |
Why?
|
| Humans | 7 | 2021 | 133540 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2010 | 947 | 0.050 |
Why?
|
| Carbon | 1 | 2022 | 99 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2022 | 78 | 0.050 |
Why?
|
| Female | 3 | 2018 | 71524 | 0.050 |
Why?
|
| Life Cycle Stages | 1 | 2020 | 28 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 101 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 83 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 97 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 444 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 723 | 0.040 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 19 | 0.040 |
Why?
|
| Macrophages | 1 | 2022 | 700 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 679 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2020 | 407 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 259 | 0.030 |
Why?
|
| Sputum | 1 | 2018 | 116 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 3412 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3067 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 13001 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 17436 | 0.010 |
Why?
|
| Aged | 1 | 2018 | 21701 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 29347 | 0.010 |
Why?
|
| Adult | 1 | 2018 | 31933 | 0.010 |
Why?
|
| Male | 1 | 2018 | 65774 | 0.010 |
Why?
|